HC Wainwright Has Optimistic Outlook of DVAX FY2026 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Dynavax Technologies in a report issued on Friday, February 21st. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will earn $0.54 per share for the year, up from their previous estimate of $0.45. HC Wainwright currently has a "Buy" rating and a $31.00 target price on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for Dynavax Technologies' FY2027 earnings at $0.69 EPS.

DVAX has been the subject of several other reports. StockNews.com upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday. The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st.

Dynavax Technologies Trading Up 1.8 %

Shares of DVAX stock traded up $0.25 during mid-day trading on Monday, hitting $13.66. The company's stock had a trading volume of 184,632 shares, compared to its average volume of 1,793,984. The company's fifty day simple moving average is $12.83 and its 200-day simple moving average is $12.06. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.05. The company has a market cap of $1.80 billion, a PE ratio of 75.99 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Deep Track Capital LP boosted its stake in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after purchasing an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Dynavax Technologies by 23,990.1% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after acquiring an additional 5,172,263 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock valued at $51,948,000 after purchasing an additional 171,933 shares during the period. Renaissance Technologies LLC lifted its position in shares of Dynavax Technologies by 1.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock valued at $30,077,000 after acquiring an additional 41,000 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its stake in Dynavax Technologies by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock worth $24,497,000 after purchasing an additional 486,981 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.